Lupus erythematosus nephropathy is one of autoimmune diseases, which belongs to connective tissue disease, due to the presence of different toxins in the body, nearly 10 years, due to the continuous improvement of immunoassay technology, especially in recent years with the combination of Chinese and Western medicine, The prognosis has a greater improvement in the quality of life of patients has been significantly improved.
Lupus erythematosus nephropathy is a kind of autoimmune disease, in recent years, the negotiable detection technology, the prognosis of the disease has been greatly improved, we talk about several types of lupus nephritis.
For lupus erythematosus nephropathy, the World Health Organization pides it into 6 types:
Type I: normal or minor lesions.
Type Ⅱ (mesangial proliferative type): glomerular mesangial cell proliferation, mesangial thickening, clinically a small amount of proteinuria and microscopic hematuria, this type of prognosis is better.
Type Ⅲ (focal proliferative type): glomerular damage does not exceed 50%. Glomerular endothelial cells showed segmental proliferation and focal necrosis, with small or medium urinary protein, hematuria, hormone therapy, and less renal failure.
Type Ⅳ (diffuse proliferation type): Glomerular damage was over 50%. Glomerular basement membrane irregular proliferation, extensive necrosis, can have severe proteinuria, tubular urine and hypertension, poor prognosis.
V (membranous): There were mesangial and basement membrane thickening, but no cell proliferation and necrosis. A large number of urinary protein, edema, hypertension and cholesterol increase, albumin decrease, hormone treatment is sometimes good and sometimes bad, prognosis changes greatly, and eventually develop into renal failure.
Ⅵ type (hardening type): glomerular sclerosis, renal failure, poor treatment, poor prognosis. The above pathological types, can transition and transformation with each other. If the lesion to proliferation, after treatment may be reversed after the disease; to hardening, the treatment effect is poor. So only early treatment, in order to prevent renal failure, in order to extend the survival of systemic lupus erythematosus.